KDR (kinase insert domain receptor)/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)

Atlas of Genetics and Cytogenetics in Oncology and Haematology ◽

10.4267/2042/66055 ◽

2018 ◽

Author(s):

Noah Sorrelle ◽

Rolf Brekken

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Kinase Insert Domain Receptor ◽

Endothelial Growth Factor

Download Full-text

Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome

Reproductive Biology and Endocrinology ◽

10.1186/1477-7827-12-36 ◽

2014 ◽

Vol 12 (1) ◽

pp. 36 ◽

Cited By ~ 2

Author(s):

Travis J O’Brien ◽

Arthur F Harralson ◽

Tuyen Tran ◽

Ian Gindoff ◽

Funda E Orkunoglu-Suer ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Genetic Variation ◽

Growth Factor ◽

Ovarian Hyperstimulation Syndrome ◽

Growth Factor Receptor ◽

Ovarian Hyperstimulation ◽

Vascular Endothelial ◽

Kinase Insert Domain Receptor ◽

Endothelial Growth Factor

Download Full-text

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

Onkologische Welt ◽

10.1055/s-0038-1631032 ◽

2012 ◽

Vol 03 (02) ◽

pp. 93-92

Author(s):

Alexander Kretzschmar

Keyword(s):

Vascular Endothelial Growth Factor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Vascular Endothelial ◽

Medulläres Schilddrüsenkarzinom ◽

Epidermal Growth ◽

Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Download Full-text

Expression des „Epidermal Growth-Factor Receptor“ (EGFR) und des „Vascular Endothelial Growth Factor“ (VEGF) bei Lymphangioleiomyomatose (LAM)

Pneumologie ◽

10.1055/s-2006-934022 ◽

2006 ◽

Vol 60 (S 1) ◽

Author(s):

H Watz ◽

K Engels ◽

M Amthor ◽

D Kirsten ◽

H Magnussen

Keyword(s):

Vascular Endothelial Growth Factor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Epidermal Growth ◽

Endothelial Growth Factor

Download Full-text

Faculty Opinions recommendation of Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1163678.625451 ◽

2009 ◽

Author(s):

David Bates

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Lymphatic Vessel ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endogenous Inhibitor ◽

Vessel Growth ◽

Alternatively Spliced ◽

Endothelial Growth Factor

Download Full-text

Faculty Opinions recommendation of Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11744956.12828054 ◽

2011 ◽

Author(s):

Asma Nusrat

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Antagonism ◽

Endothelial Growth Factor ◽

Α2β1 Integrin

Download Full-text

Faculty Opinions recommendation of Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11744956.13740054 ◽

2011 ◽

Author(s):

Richard L Stevens

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Antagonism ◽

Endothelial Growth Factor ◽

Α2β1 Integrin

Download Full-text

Faculty Opinions recommendation of 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697854.793153053 ◽

2012 ◽

Author(s):

Hendrik van Poppel ◽

Yuri Tolkach

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Neoadjuvant Treatment ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

Receptor Inhibitor

Download Full-text

Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines

Molecular Carcinogenesis ◽

10.1002/mc.21969 ◽

2012 ◽

Vol 53 (3) ◽

pp. 230-242 ◽

Cited By ~ 1

Author(s):

Elizabeth A. Beierle ◽

Xiaojie Ma ◽

Jerry E. Stewart ◽

Michael Megison ◽

William G. Cance ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Focal Adhesion ◽

Neuroblastoma Cell ◽

Growth Factor Receptor ◽

Human Neuroblastoma Cell ◽

Vascular Endothelial ◽

Human Neuroblastoma ◽

Endothelial Growth Factor ◽

Neuroblastoma Cell Lines

Download Full-text

Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase

Analytical Biochemistry ◽

10.1016/j.ab.2006.10.038 ◽

2007 ◽

Vol 360 (2) ◽

pp. 196-206 ◽

Cited By ~ 4

Author(s):

Genshi Zhao ◽

Robert B. Peery ◽

Jonathan M. Yingling

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinase ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Peptide Substrate ◽

Endothelial Growth Factor

Download Full-text

Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation

The Oncologist ◽

10.1002/onco.13897 ◽

2021 ◽

Author(s):

Akhilesh Sivakumar ◽

Sarah E. Caulfield ◽

Chao Zhang ◽

Subir Goyal ◽

Mehmet A. Bilen ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Retrospective Study ◽

Growth Factor ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Bleeding Risk ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text